Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor.
Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.
Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.